Directorate change

RNS Number : 7612C

Premaitha Health PLC

03 October 2018

 

Premaitha Health PLC

("Premaitha" or the "Company")

Directorate change

Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing ("NIPT"), announces that, further to the announcement made by the Company on 20 September 2018, Mr Hayden Jeffreys has been appointed as Group Commercial Director to the Company following completion of customary director due diligence. Mr Jeffreys will take up his position on the Board of Premaitha with immediate effect.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Mr Hayden William Jeffreys (aged 42):

Current Appointments	Appointments in the last 5 years
Cambridge DX Limited	Delta Biologicals Srl
	Diamedix Inc
	Drew Scientific Inc
	Erba Diagnostics Inc
	Erba Diagnostics Mexico S.A.
	Erba Mannheim Gmbh
	Immunovision Inc
	Jas Diagnostics Inc
	Lumora Limited

There is no further information regarding Mr Jeffreys required to be disclosed under the AIM Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Enquiries

Premaitha Health plc	Tel: [phone]
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing
[e-mail]
Cairn Financial Advisers LLP (Nomad)	Tel: [phone]
Liam Murray / James Caithie
finnCap (Broker)	Tel: [phone]
Geoff Nash / Matthew Radley (Corporate Finance)
Tim Redfern (Corporate Broking)
Vigo Communications	Tel: [phone]
Ben Simons / Fiona Henson / Antonia Pollock
[e-mail]

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha's IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of placental DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

 

END

 

 

BOAUGGAAUUPRGQP